A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.
Vincenzo CostanzoYashwant Kumar RatreEmanuela AndrettaRakesh AcharyaL V K S BhaskarHenu Kumar VermaPublished in: Current treatment options in oncology (2024)
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
Keyphrases
- drug induced
- liver injury
- radiation induced
- papillary thyroid
- oxidative stress
- squamous cell
- blood pressure
- type diabetes
- randomized controlled trial
- young adults
- risk assessment
- climate change
- skeletal muscle
- room temperature
- ionic liquid
- induced apoptosis
- human health
- angiotensin converting enzyme
- signaling pathway
- heat shock protein